All In Biotech

Drug Trial Radar · NCT02823145

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome

Last checked: Nov 20, 2026Latest source record: Jul 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

375

Actual

Start

Jun 8, 2016

Primary completion

Jan 27, 2023

Study completion Jan 27, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 6, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome.

Conditions

  • Dravet Syndrome

Interventions

  • ZX008 (Fenfluramine Hydrochloride)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Open-label Extension (OLE) Treatment PeriodTime frame: From Day 1 to End of OLE Treatment Period - End of Study (EOS) Visit (Month 42)
  2. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the OLE Treatment PeriodTime frame: From Day 1 to End of OLE Treatment Period - EOS Visit (Month 42)
  3. Percentage of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the OLE Treatment PeriodTime frame: From Day 1 to End of OLE Treatment Period - EOS Visit (Month 42)

Locations

67 sites in 12 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Center for Neurosciences - Tucson

    Tucson, Arizona

  • Children's Hospital of Orange County

    Orange, California

  • Rady Children's Hospital San Diego

    San Diego, California

  • University of California San Francisco

    San Francisco, California

  • The Children's Hospital Colorado

    Aurora, Colorado

  • NW FL Clinical Research Group, LLC

    Gulf Breeze, Florida

  • Miami Children's Hospital Brain Institute

    Miami, Florida

  • Neurology and Epilepsy Research Center

    Orlando, Florida

  • Clinical Integrative Research Center of Atlanta, Panda Neurology

    Atlanta, Georgia

  • Ann and Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Boston Children's Hospital

    Boston, Massachusetts

  • Children's Hospital Of Michigan

    Detroit, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Minnesota Epilepsy Group, P.A.

    Saint Paul, Minnesota

  • Institute of Neurology and Neurosurgery at St. Barnabus

    Livingston, New Jersey

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Le Bonheur Children's Hospital

    Memphis, Tennessee

  • Cook Children's Medical Center

    Fort Worth, Texas

  • University of Utah

    Salt Lake City, Utah

  • Seattle Children's Hospital

    Seattle, Washington

  • MultiCare Institute for Research & Innovation

    Tacoma, Washington

  • Melbourne Brain Centre Austin Hospital

    Heidelberg, Australia

  • Children's Health Queensland Hospital and Health Service at Lady Cilento Children's Hospital

    South Brisbane, Australia

  • The Children's Hospital Westmead Dept. of Neurology and Neurosurgery

    Westmead, Australia

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • Centre Hospitalier Universitaire Sainte-Justine

    Montreal, Canada

  • British Columbia Children's Hospital

    Vancouver, Canada

  • Danish National Epilepsy Centre

    Dianalund, Denmark

  • CHU Amiens-Picardie Service De Neurologie Pediatrique

    Amiens, France

  • CHU De Bordeaux Service De Pédiatrie Médicale

    Bordeaux, France

  • CHRU Lille Antenne Pédiatrique Du CIC - Hôpital Jeanne De Flandre

    Lille, France

  • HOPITAL DEL LA TIMONE - HOPITAL HENRI GASTAUT Hôpital De La Timone Neurologie Pédiatrique Pneumologie Pédiatrique Et Médecine Infantile

    Marseille, France

  • Hôpital Robert Debré Pôle: Pédiatrie Médicale Service: Neurologie Et Maladies Métaboliques

    Paris, France

  • Hôpital Universitaire Necker-Enfants Malades Service de neurologie pédiatrique Centre de référence épilepsies rares (CReER)

    Paris, France

  • DRK Kliniken Berlin - Westend Epilepsiezentrum / Neuropaediatrie

    Berlin, Germany

  • Krankenhaus Mara Epilepsie-Zentrum Bethel

    Bielefeld, Germany

  • Universitaetsklinikum Freiburg Zentrum fuer Kinder- und Jugendmedizin

    Freiburg im Breisgau, Germany

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.